ID BIOMEDICAL LICENSES PE BIOSYSTEMS TO USE CYCLING PROBE� TECHNOLOGY FOR GENOMICS, SINGLE NUCLEOTIDE POLYMORPHISMS (SNP�S) AND OTHER USES

VANCOUVER, BC - June 19, 2000 - ID Biomedical Corporation (Nasdaq: IDBE) and PE Biosystems Group (NYSE: PEB) announced today that they have entered into a worldwide, non-exclusive license granting PE Biosystems access to ID Biomedical�s intellectual property concerning its Cycling Probe� Technology. The license will allow PE Biosystems to use the intellectual property in a number of areas, including genomics, high throughput screening and the development of assays to detect nucleic acid sequences.

Under the agreement, PE Biosystems will pay ID Biomedical royalties based on future product sales, as well as an up-front license fee of US$5 million, a portion of which will be creditable against royalties. Anthony Holler, M.D., President of ID Biomedical said: "One of our development strategies is to implement our proprietary technology in the rapidly emerging fields of nucleic acid detection, including genomics and the detection of single nucleotide polymorphisms or SNP�s. PE Biosystems has established a leading position in the development of instruments, reagents and software used throughout the academic research, biotechnology, pharmaceutical and applied markets, so we are obviously very pleased with this arrangement. As we continue to implement our strategic plan, we expect to enter into other alliances and licensing agreements relative to the use of Cycling Probe� Technology in genomics."

Michael Hunkapiller, Ph.D., President of PE Biosystems and Senior Vice President of PE Corporation said: "The sequencing of the human and other genomes, together with the understanding of the roles of genes in cellular function, will provide information to help life scientists understand the logic of biology. As a provider of key enabling genomics technology, we are constantly looking for new technologies that may facilitate our customer�s ability to produce and use genetic information. In this regard, we look forward to exploring the possibilities offered by Cycling Probe� Technology."

PE Corporation comprises two operating groups. The PE Biosystems Group with sales of $1.2 billion during fiscal 1999, develops and markets instrument-based systems, reagents, software and contract services to the life science industry and research community. PE Biosystems is headquartered in Foster City, Calif., and comprises four divisions: Applied Biosystems, PE Informatics, PerSeptive Biosystems, and Tropix. Celera Genomics Group (NYSE: CRA), headquartered in Rockville, MD, intends to become the definitive source of genomic and related medical information. Information about the company, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the worldwide web at www.pecorporation.com or by phoning 800.762.6923.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "intend," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements are based on PE Corporation�s current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, PE Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of PE Biosystems businesses include but are not limited to (1) rapidly changing technology and dependence on new products; (2) sales dependent on customers� capital spending policies and government-sponsored research; (3) claims for patent infringement; (4) significant overseas operations; (5) future growth strategy; (6) earthquakes; and (7) other factors that might be described from time to time in PE Corporation�s filings with the Securities and Exchange Commission.

ID Biomedical Corporation is a North American based biopharmaceutical company focused on the development of proprietary vaccine and immunotherapeutic products. The Company�s lead product, a vaccine for the prevention of group A streptococcal diseases, StreptAvax�, is in a Phase I Clinical Trial sponsored and funded by the National Institute of Allergy and Infectious Diseases. Other vaccine products under development include: a vaccine for the prevention of tuberculosis which has been licensed to Aventis Pasteur, the vaccine subsidiary of Aventis S.A (formally Rh�ne-Poulanc/Hoechst), a therapeutic vaccine for the prevention of AIDS and a vaccine for the prevention of disease caused by deadly strains of the E. coli bacteria. ID Biomedical is also developing a proprietary gene identification system, Cycling Probe� Technology, for applications in genomics and diagnostics. Using Cycling Probe� Technology, the Company is developing rapid tests that identify antibiotic resistant bacteria from culture. The Company�s first two products are being distributed by Alexon-Trend, Inc., a subsidiary of Sybron International (NYSE: SYB) and Mitsubishi Chemical Corporation. Information about the Company, including reports and other information filed by the Company with the U.S. Securities and Exchange Commission, is available on the worldwide web at http://www.idbiomedical.com/ or by phoning 604.431.9314.

The foregoing information contains so-called forward-looking statements. These include statements about our expectations, beliefs, intentions or strategies for the future, which we indicate by words or phrases such as "anticipate", "expect", "intend", "plan", "will", "we believe", "the Company believes", "management believes" and similar language. All forward-looking statements are based on our current expectations and are subject to risks uncertainties and to assumptions we have made. Important factors that could cause our actual results to differ materially from those expressed or implied by such forward-looking statements include i) the Company's ability to successfully complete preclinical and clinical development of its products; ii) our ability to obtain and enforce timely patent and intellectual property protection for its technology and products; iii) our ability to avoid, either by product design, licensing arrangement or otherwise, infringement of third parties� intellectual property; iv) decisions ,and the timing of decisions, made by the health regulatory agencies regarding approval of the Company's products for human testing; v) the Company�s ability to complete and maintain corporate alliances relating to the development and commercialization of its technology and products, vi)market acceptance of the Company�s technology and products, and (vii) the competitive environment and impact of technological change. We base our forward-looking statements on information currently available to us, and we assume no obligation to update them.

Copyright � 2000. PE Corporation. All Rights Reserved.
Celera, Celera Genomics, and PE Biosystems are trademarks of PE Corporation.